Market closed
Halozyme Therapeutics/$HALO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
373
Website
HALO Metrics
BasicAdvanced
$5.8B
Market cap
15.12
P/E ratio
$3.02
EPS
1.27
Beta
-
Dividend rate
Price and volume
Market cap
$5.8B
Beta
1.27
52-week high
$65.53
52-week low
$33.15
Average daily volume
1.7M
Financial strength
Current ratio
10.357
Quick ratio
8.749
Long term debt to equity
341.186
Total debt to equity
341.186
Interest coverage (TTM)
25.41%
Management effectiveness
Return on assets (TTM)
14.87%
Return on equity (TTM)
111.83%
Valuation
Price to earnings (TTM)
15.119
Price to revenue (TTM)
6.15
Price to book
12.84
Price to tangible book (TTM)
-15.15
Price to free cash flow (TTM)
14.835
Growth
Revenue change (TTM)
21.35%
Earnings per share change (TTM)
61.71%
3-year revenue growth (CAGR)
26.95%
3-year earnings per share growth (CAGR)
2.82%
What the Analysts think about HALO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
HALO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HALO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $5.8B as of November 23, 2024.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 15.12 as of November 23, 2024.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.